Trial Profile
A Phase IV Multi-Centric, Post-Marketing Study Evaluating the Safety, Immunogenicity and Efficacy of the Marketed Formulation of Hetero-Adalimumab
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Axial spondyloarthritis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
- Focus Adverse reactions
- Sponsors Hetero Drugs
- 13 Nov 2018 New trial record